Around half of the pharmaceutical products launched in the USA in 2023 underperformed, and 39% overperformed, according to ...

USA-based Acadia Pharmaceuticals has entered into a definitive asset purchase agreement to sell its Rare Pediatric Disease ...

PrognomiQ has raised $34 million in a series D round led by Seer, boosting its total funding to over $135 million. The funds ...

Some of the UK’s leading academics and industry professionals have welcomed Chancellor Rachel Reeves’ £520 million ($669 ...

GSK’s Arexvy has received expanded approval in Canada for preventing RSV-related lower respiratory tract disease in adults ...

The congress is a collaboration of the European Society for Medical Oncology (ESMO), the European SocieTy for Radiotherapy ...

French pharma major Sanofi’s Dupixent (dupilumab), which notched up sales of 3.5 billion euros ($3.8 billion) in ...

Plus Therapeutics has partnered with SpectronRx for the production of Rhenium (186Re) obisbemeda, a targeted radiotherapy for ...

Beam Therapeutics will present new data on its sickle cell disease (SCD) therapies at the ASH meeting, including results from ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) issued final guidance recommending ...

India’s Sun Pharma has been blocked in its efforts to launch its JAK inhibitor Leqselvi (deuruxolitinib) in the USA.

The ROS1 inhibitor market for NSCLC, valued at around $290 million in 2023 across the USA, Europe, and Japan, is set for growth with new-generation therapies targeting resistance mutations.